INVIVO
InVivo BioTech Services GmbH
a BRUKER company

SARS-CoV-2 Spike Protein S1-Receptor-Binding Domain-Mu (B.1.621)_HEK

Description:

InVivo offers a recombinant form of the Spike protein receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in HEK-INV cells (InVivo proprietary optimized; human embryonic kidney, HEK293 cells).

RBD-Mu (B.1.621) variant; containing mutations R346K, E484K, N501Y.

Protein design and manufacturing process is based on InVivo's RBD protein (aa 319-541). The protein includes a C-terminal hexa-histidine-tag and is purified using affinity chromatography (AC) and preparative SEC (for polishing).

Product-ID:	S1-RBD-Mu (B.1.621)_HEK
Expression System:	Mammalian; HEK
Protein Accession Number:	GenBank: QHD43416.1 / UniProt: P0DTC2
Amino Acids:	Arg319–Phe541, modified as mentioned above
Mutations:	R346K, E484K, N501Y
Mature Protein N-Term:	Arg319 (predicted)
Tag:	6 x His-Tag; C-terminal
Expected Molecular Weight:	26 kDa (*glycosylated form runs at 25-40 kDa in gel electrophoresis)*
Formulation:	Liquid, 20 mM NaPP, 300 mM NaCl pH 7.2
Concentration:	≥ 0.5 mg/ mL
Purity:	≥ 90% (*via analytical CGE under reducing conditions*)
Recommended storage temp:	< –15°C
Shipping condition:	on dry ice

The product is for research use or for further manufacturing only.



SARS-CoV-2 receptor-binding domains (RBD-Wuhan, Delta, Delta plus, Lambda, Eta and Mu) recombinantly expressed in HEK cells tested as solid phase bound capture antigens at 2 µg/mL in an in-house SARS-CoV-2 IgG ELISA.

14 SARS-CoV-2 positive patient serum samples (obtained before October 2020) were applied. The line indicates the median of the absorbance values.